Related Experiment Video
Updated: Mar 9, 2026
08:54
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
8.3K
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis
Greg J Fox1, Andrea Benedetti2, Helen Cox3
1Central Clinical School, University of Sydney, Camperdown, Australia.
The European Respiratory Journal
|January 4, 2017
Summary
Group 5 drugs are debated for multidrug-resistant tuberculosis (MDR-TB). This meta-analysis found no improved treatment success with clofazimine, amoxicillin/clavulanic acid, or macrolides in MDR-TB patients.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health challenge.
- The efficacy of 'group 5' second-line drugs in MDR-TB treatment regimens is not well-established.
- There is a need for evidence-based treatment strategies for drug-resistant tuberculosis.
Purpose of the Study:
- To evaluate the effectiveness of specific group 5 drugs in treating patients with MDR-TB.
- To compare treatment success rates for patients receiving different group 5 antibiotics.
- To provide data to inform clinical guidelines for MDR-TB management.
Main Methods:
- Individual patient data meta-analysis of 31 published cohort studies on MDR-TB therapy.
- Inclusion of data from 9282 patients, with 2191 receiving at least one group 5 drug.
- Random effects meta-analysis to pool treatment outcomes and compare success rates.
Main Results:
- No significant improvement in treatment success was observed for clofazimine, amoxicillin/clavulanic acid, or macrolide antibiotics.
- Thioacetazone showed a potential association with increased treatment success, but this finding was heavily influenced by a single study.
- Statistical methods were employed to control for confounding factors in the analysis.
Conclusions:
- Current evidence does not support the routine use of clofazimine, amoxicillin/clavulanic acid, or macrolides as effective agents for MDR-TB.
- The role of thioacetazone requires further investigation with cautious interpretation due to study limitations.
- Development of novel and effective antibiotics for drug-resistant TB remains a critical priority.
Related Concept Videos
01:28Pulmonary Tuberculosis V
719
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
719
01:29Therapeutic Drug Monitoring: Affecting Factors
306
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
306
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
266
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
266
01:27Combined Effects of Drugs: Synergism
7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.1K
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
244
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
244
01:12Analysis of Population Pharmacokinetic Data
888
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
888